HEADER HYDROLASE 16-NOV-10 2XY9 TITLE HUMAN ANGIOTENSIN CONVERTING ENZYME IN COMPLEX WITH PHOSPHINIC TITLE 2 TRIPEPTIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANGIOTENSIN-CONVERTING ENZYME; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 71-654; COMPND 5 SYNONYM: ACE, DIPEPTIDYL CARBOXYPEPTIDASE I, KININASE II, CD143; COMPND 6 EC: 3.4.15.1; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 ORGAN: TESTIS; SOURCE 6 EXPRESSION_SYSTEM: CRICETULUS GRISEUS; SOURCE 7 EXPRESSION_SYSTEM_COMMON: CHINESE HAMSTER; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 10029; SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: CHINESE HAMSTER OVARY CELLS; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PLEN/PEE14 KEYWDS HYDROLASE, ZINC METALLOPROTEASE, METALLOPEPTIDASE EXPDTA X-RAY DIFFRACTION AUTHOR M.AKIF,S.L.SCHWAGER,C.S.ANTHONY,B.CZARNY,F.BEAU,V.DIVE,E.D.STURROCK, AUTHOR 2 K.R.ACHARYA REVDAT 4 20-DEC-23 2XY9 1 HETSYN REVDAT 3 29-JUL-20 2XY9 1 COMPND REMARK HETNAM LINK REVDAT 3 2 1 SITE ATOM REVDAT 2 11-APR-12 2XY9 1 REMARK VERSN REVDAT 1 11-MAY-11 2XY9 0 JRNL AUTH M.AKIF,S.L.SCHWAGER,C.S.ANTHONY,B.CZARNY,F.BEAU,V.DIVE, JRNL AUTH 2 E.D.STURROCK,K.R.ACHARYA JRNL TITL NOVEL MECHANISM OF INHIBITION OF HUMAN JRNL TITL 2 ANGIOTENSIN-I-CONVERTING ENZYME (ACE) BY A HIGHLY SPECIFIC JRNL TITL 3 PHOSPHINIC TRIPEPTIDE. JRNL REF BIOCHEM.J. V. 436 53 2011 JRNL REFN ISSN 0264-6021 JRNL PMID 21352096 JRNL DOI 10.1042/BJ20102123 REMARK 2 REMARK 2 RESOLUTION. 1.97 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0072 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.97 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.65 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 97.8 REMARK 3 NUMBER OF REFLECTIONS : 45842 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.201 REMARK 3 R VALUE (WORKING SET) : 0.199 REMARK 3 FREE R VALUE : 0.232 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 2442 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.97 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.02 REMARK 3 REFLECTION IN BIN (WORKING SET) : 3176 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 92.58 REMARK 3 BIN R VALUE (WORKING SET) : 0.2590 REMARK 3 BIN FREE R VALUE SET COUNT : 144 REMARK 3 BIN FREE R VALUE : 0.3070 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4738 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 187 REMARK 3 SOLVENT ATOMS : 430 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 22.50 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.94 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.00000 REMARK 3 B22 (A**2) : 0.00000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.188 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.160 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.111 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.846 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.941 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.925 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 5076 ; 0.007 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6910 ; 1.203 ; 1.977 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 578 ; 5.021 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 244 ;34.804 ;24.180 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 804 ;13.805 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 26 ;17.450 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 728 ; 0.117 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3908 ; 0.005 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2922 ; 0.403 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 4711 ; 0.780 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 2154 ; 1.076 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 2199 ; 1.827 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. RESIDUES 435-438 ARE DISORDERED. REMARK 4 REMARK 4 2XY9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 16-NOV-10. REMARK 100 THE DEPOSITION ID IS D_1290046267. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 13-MAR-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.7 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I04 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9763 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 49449 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.970 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.8 REMARK 200 DATA REDUNDANCY : 4.000 REMARK 200 R MERGE (I) : 0.07000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.97 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.04 REMARK 200 COMPLETENESS FOR SHELL (%) : 93.4 REMARK 200 DATA REDUNDANCY IN SHELL : 4.00 REMARK 200 R MERGE FOR SHELL (I) : 0.31000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: PDB ENTRY 1O8A REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.50 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 13.5% PEG4000,50MM SODIUM ACETATE, PH REMARK 280 4.7 AND 0.01MM ZNSO4 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 29.36500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 67.40750 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.04700 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 67.40750 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.36500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.04700 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 435 REMARK 465 GLU A 436 REMARK 465 GLY A 437 REMARK 465 GLY A 438 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 64 CG CD OE1 OE2 REMARK 470 SER A 298 OG REMARK 470 ASP A 440 CG OD1 OD2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 72 75.36 -174.87 REMARK 500 GLU A 123 -131.63 47.86 REMARK 500 LYS A 363 -35.63 -135.95 REMARK 500 GLN A 554 -3.96 81.48 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 ZN A1628 ZN REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS A 383 NE2 REMARK 620 2 HIS A 387 NE2 103.8 REMARK 620 3 GLU A 411 OE1 91.6 104.6 REMARK 620 4 3ES A1635 OAG 101.5 97.3 151.0 REMARK 620 N 1 2 3 REMARK 630 REMARK 630 MOLECULE TYPE: NULL REMARK 630 MOLECULE NAME: [(2S)-2-({3-[HYDROXYL(2-PHENYL-(1R)-1-{[(BENZYLOXY) REMARK 630 [(2S)-2-({3-[HYDROXYL(2-PHENYL-(1R)-1-CARBONYL]-AMINO}ETHYL) REMARK 630 PHOSPHINYL]-2-[(3-PHENYLISOXAZOL-5-YL)METHYL]-1-OXO-PROPYL}AMINO)- REMARK 630 3-(4-HYDROXY-PHENYL) REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 3ES A 1635 REMARK 630 3ES A 1636 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: PHQ PPH 1JQ TYR REMARK 630 DETAILS: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2IUL RELATED DB: PDB REMARK 900 HUMAN TACE G13 MUTANT REMARK 900 RELATED ID: 2IUX RELATED DB: PDB REMARK 900 HUMAN TACE MUTANT G1234 REMARK 900 RELATED ID: 1UZE RELATED DB: PDB REMARK 900 COMPLEX OF THE ANTI-HYPERTENSIVE DRUG ENALAPRIL AN THE HUMAN REMARK 900 TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME REMARK 900 RELATED ID: 2C6F RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN SOMATIC ANGIONTENSIN-I CONVERTING ENZYME N DOMAIN REMARK 900 RELATED ID: 1UZF RELATED DB: PDB REMARK 900 COMPLEX OF THE ANTI-HYPERTENSIVE DRUG CAPTOPRIL AN THE HUMAN REMARK 900 TESTICULAR ANGIOTENSIN I-CONVERTING ENZYME REMARK 900 RELATED ID: 1O8A RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN CONVERING ENZYME (NATIVE). REMARK 900 RELATED ID: 2C6N RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN SOMATIC ANGIONTENSIN-I CONVERTING ENZYME N REMARK 900 DOMAIN WITH LISINOPRIL REMARK 900 RELATED ID: 1O86 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN ANGIOTENSIN CONVERING ENZYME IN COMPLEX REMARK 900 WITH LISINOPRIL. REMARK 900 RELATED ID: 2XYD RELATED DB: PDB REMARK 900 HUMAN ANGIOTENISN CONVERTING ENZYME N-DOMAIN IN COMPLEX WITH REMARK 900 PHOSPHINIC TRIPEPTIDE REMARK 999 REMARK 999 SEQUENCE REMARK 999 UNDERGLYCOSYLATED MUTANT LACKING FIRST 36 N-TERMINAL, REMARK 999 CYTOPLASMIC, AND TRANSMEMBRANE DOMAIN RESIDUES. DBREF 2XY9 A 40 623 UNP P12821 ACE_HUMAN 71 654 SEQADV 2XY9 ALA A 624 UNP P12821 EXPRESSION TAG SEQRES 1 A 585 ASP GLU ALA GLU ALA SER LYS PHE VAL GLU GLU TYR ASP SEQRES 2 A 585 ARG THR SER GLN VAL VAL TRP ASN GLU TYR ALA GLU ALA SEQRES 3 A 585 ASN TRP ASN TYR ASN THR ASN ILE THR THR GLU THR SER SEQRES 4 A 585 LYS ILE LEU LEU GLN LYS ASN MET GLN ILE ALA ASN HIS SEQRES 5 A 585 THR LEU LYS TYR GLY THR GLN ALA ARG LYS PHE ASP VAL SEQRES 6 A 585 ASN GLN LEU GLN ASN THR THR ILE LYS ARG ILE ILE LYS SEQRES 7 A 585 LYS VAL GLN ASP LEU GLU ARG ALA ALA LEU PRO ALA GLN SEQRES 8 A 585 GLU LEU GLU GLU TYR ASN LYS ILE LEU LEU ASP MET GLU SEQRES 9 A 585 THR THR TYR SER VAL ALA THR VAL CYS HIS PRO ASN GLY SEQRES 10 A 585 SER CYS LEU GLN LEU GLU PRO ASP LEU THR ASN VAL MET SEQRES 11 A 585 ALA THR SER ARG LYS TYR GLU ASP LEU LEU TRP ALA TRP SEQRES 12 A 585 GLU GLY TRP ARG ASP LYS ALA GLY ARG ALA ILE LEU GLN SEQRES 13 A 585 PHE TYR PRO LYS TYR VAL GLU LEU ILE ASN GLN ALA ALA SEQRES 14 A 585 ARG LEU ASN GLY TYR VAL ASP ALA GLY ASP SER TRP ARG SEQRES 15 A 585 SER MET TYR GLU THR PRO SER LEU GLU GLN ASP LEU GLU SEQRES 16 A 585 ARG LEU PHE GLN GLU LEU GLN PRO LEU TYR LEU ASN LEU SEQRES 17 A 585 HIS ALA TYR VAL ARG ARG ALA LEU HIS ARG HIS TYR GLY SEQRES 18 A 585 ALA GLN HIS ILE ASN LEU GLU GLY PRO ILE PRO ALA HIS SEQRES 19 A 585 LEU LEU GLY ASN MET TRP ALA GLN THR TRP SER ASN ILE SEQRES 20 A 585 TYR ASP LEU VAL VAL PRO PHE PRO SER ALA PRO SER MET SEQRES 21 A 585 ASP THR THR GLU ALA MET LEU LYS GLN GLY TRP THR PRO SEQRES 22 A 585 ARG ARG MET PHE LYS GLU ALA ASP ASP PHE PHE THR SER SEQRES 23 A 585 LEU GLY LEU LEU PRO VAL PRO PRO GLU PHE TRP ASN LYS SEQRES 24 A 585 SER MET LEU GLU LYS PRO THR ASP GLY ARG GLU VAL VAL SEQRES 25 A 585 CYS HIS ALA SER ALA TRP ASP PHE TYR ASN GLY LYS ASP SEQRES 26 A 585 PHE ARG ILE LYS GLN CYS THR THR VAL ASN LEU GLU ASP SEQRES 27 A 585 LEU VAL VAL ALA HIS HIS GLU MET GLY HIS ILE GLN TYR SEQRES 28 A 585 PHE MET GLN TYR LYS ASP LEU PRO VAL ALA LEU ARG GLU SEQRES 29 A 585 GLY ALA ASN PRO GLY PHE HIS GLU ALA ILE GLY ASP VAL SEQRES 30 A 585 LEU ALA LEU SER VAL SER THR PRO LYS HIS LEU HIS SER SEQRES 31 A 585 LEU ASN LEU LEU SER SER GLU GLY GLY SER ASP GLU HIS SEQRES 32 A 585 ASP ILE ASN PHE LEU MET LYS MET ALA LEU ASP LYS ILE SEQRES 33 A 585 ALA PHE ILE PRO PHE SER TYR LEU VAL ASP GLN TRP ARG SEQRES 34 A 585 TRP ARG VAL PHE ASP GLY SER ILE THR LYS GLU ASN TYR SEQRES 35 A 585 ASN GLN GLU TRP TRP SER LEU ARG LEU LYS TYR GLN GLY SEQRES 36 A 585 LEU CYS PRO PRO VAL PRO ARG THR GLN GLY ASP PHE ASP SEQRES 37 A 585 PRO GLY ALA LYS PHE HIS ILE PRO SER SER VAL PRO TYR SEQRES 38 A 585 ILE ARG TYR PHE VAL SER PHE ILE ILE GLN PHE GLN PHE SEQRES 39 A 585 HIS GLU ALA LEU CYS GLN ALA ALA GLY HIS THR GLY PRO SEQRES 40 A 585 LEU HIS LYS CYS ASP ILE TYR GLN SER LYS GLU ALA GLY SEQRES 41 A 585 GLN ARG LEU ALA THR ALA MET LYS LEU GLY PHE SER ARG SEQRES 42 A 585 PRO TRP PRO GLU ALA MET GLN LEU ILE THR GLY GLN PRO SEQRES 43 A 585 ASN MET SER ALA SER ALA MET LEU SER TYR PHE LYS PRO SEQRES 44 A 585 LEU LEU ASP TRP LEU ARG THR GLU ASN GLU LEU HIS GLY SEQRES 45 A 585 GLU LYS LEU GLY TRP PRO GLN TYR ASN TRP THR PRO ALA MODRES 2XY9 ASN A 72 ASN GLYCOSYLATION SITE MODRES 2XY9 ASN A 109 ASN GLYCOSYLATION SITE HET NAG B 1 14 HET NAG B 2 14 HET BMA B 3 11 HET FUC B 4 10 HET ACT A1625 4 HET CL A1626 1 HET CL A1627 1 HET ZN A1628 1 HET NAG A1631 14 HET EPE A1634 15 HET 3ES A1635 51 HET 3ES A1636 51 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM BMA BETA-D-MANNOPYRANOSE HETNAM FUC ALPHA-L-FUCOPYRANOSE HETNAM ACT ACETATE ION HETNAM CL CHLORIDE ION HETNAM ZN ZINC ION HETNAM EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID HETNAM 3ES [(2S)-2-({3-[HYDROXYL(2-PHENYL-(1R)-1-{[(BENZYLOXY) HETNAM 2 3ES [(2S)-2-({3-[HYDROXYL(2-PHENYL-(1R)-1-CARBONYL]- HETNAM 3 3ES AMINO}ETHYL)PHOSPHINYL]-2-[(3-PHENYLISOXAZOL-5-YL) HETNAM 4 3ES METHYL]-1-OXO-PROPYL}AMINO)-3-(4-HYDROXY-PHENYL) HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN BMA BETA-D-MANNOSE; D-MANNOSE; MANNOSE HETSYN FUC ALPHA-L-FUCOSE; 6-DEOXY-ALPHA-L-GALACTOPYRANOSE; L- HETSYN 2 FUC FUCOSE; FUCOSE HETSYN EPE HEPES FORMUL 2 NAG 3(C8 H15 N O6) FORMUL 2 BMA C6 H12 O6 FORMUL 2 FUC C6 H12 O5 FORMUL 3 ACT C2 H3 O2 1- FORMUL 4 CL 2(CL 1-) FORMUL 6 ZN ZN 2+ FORMUL 8 EPE C8 H18 N2 O4 S FORMUL 9 3ES 2(C38 H38 N3 O9 P) FORMUL 11 HOH *430(H2 O) HELIX 1 1 ASP A 40 THR A 71 1 32 HELIX 2 2 THR A 74 ARG A 100 1 27 HELIX 3 3 ASP A 103 LEU A 107 5 5 HELIX 4 4 ASN A 109 ASP A 121 1 13 HELIX 5 5 LEU A 122 LEU A 127 5 6 HELIX 6 6 PRO A 128 ALA A 149 1 22 HELIX 7 7 PRO A 163 SER A 172 1 10 HELIX 8 8 LYS A 174 ALA A 189 1 16 HELIX 9 9 ALA A 189 LEU A 194 1 6 HELIX 10 10 PHE A 196 ASN A 211 1 16 HELIX 11 11 ASP A 215 MET A 223 1 9 HELIX 12 12 SER A 228 LEU A 240 1 13 HELIX 13 13 LEU A 240 GLY A 260 1 21 HELIX 14 14 TRP A 283 ASN A 285 5 3 HELIX 15 15 ILE A 286 VAL A 291 1 6 HELIX 16 16 ASP A 300 GLN A 308 1 9 HELIX 17 17 THR A 311 LEU A 326 1 16 HELIX 18 18 PRO A 332 SER A 339 1 8 HELIX 19 19 ASN A 374 TYR A 394 1 21 HELIX 20 20 PRO A 398 ARG A 402 5 5 HELIX 21 21 ASN A 406 SER A 422 1 17 HELIX 22 22 THR A 423 LEU A 430 1 8 HELIX 23 23 SER A 439 ILE A 455 1 17 HELIX 24 24 ALA A 456 ASP A 473 1 18 HELIX 25 25 ASN A 480 GLY A 494 1 15 HELIX 26 26 PHE A 506 LYS A 511 5 6 HELIX 27 27 TYR A 520 ALA A 541 1 22 HELIX 28 28 PRO A 546 CYS A 550 5 5 HELIX 29 29 SER A 555 LYS A 567 1 13 HELIX 30 30 PRO A 573 GLY A 583 1 11 HELIX 31 31 ALA A 589 HIS A 610 1 22 SHEET 1 AA 2 THR A 150 CYS A 152 0 SHEET 2 AA 2 CYS A 158 GLN A 160 -1 O LEU A 159 N VAL A 151 SHEET 1 AB 2 ILE A 270 PRO A 271 0 SHEET 2 AB 2 LEU A 495 CYS A 496 1 N CYS A 496 O ILE A 270 SHEET 1 AC 2 SER A 355 ASP A 358 0 SHEET 2 AC 2 PHE A 365 LYS A 368 -1 O ARG A 366 N TRP A 357 SSBOND 1 CYS A 152 CYS A 158 1555 1555 2.29 SSBOND 2 CYS A 352 CYS A 370 1555 1555 2.04 SSBOND 3 CYS A 538 CYS A 550 1555 1555 2.03 LINK ND2 ASN A 72 C1 NAG A1631 1555 1555 1.45 LINK ND2 ASN A 109 C1 NAG B 1 1555 1555 1.44 LINK O4 NAG B 1 C1 NAG B 2 1555 1555 1.45 LINK O6 NAG B 1 C1 FUC B 4 1555 1555 1.44 LINK O4 NAG B 2 C1 BMA B 3 1555 1555 1.45 LINK NE2 HIS A 383 ZN ZN A1628 1555 1555 2.02 LINK NE2 HIS A 387 ZN ZN A1628 1555 1555 2.02 LINK OE1 GLU A 411 ZN ZN A1628 1555 1555 1.96 LINK ZN ZN A1628 OAG 3ES A1635 1555 1555 2.05 CISPEP 1 GLU A 162 PRO A 163 0 3.25 CRYST1 58.730 86.094 134.815 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017027 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011615 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007418 0.00000